Clinical Trials Logo

Clinical Trial Summary

This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To compare the immunogenicity at week 12 of a MUC1 peptide vaccine with adjuvant (MUC1 peptide-poly-ICLC adjuvant vaccine) (administered at 0, 2, and 10 weeks) in participants with a history of an advanced adenoma, randomized to receive MUC1 peptide vaccine versus placebo.

SECONDARY OBJECTIVES:

I. To evaluate the ability of the vaccine to elicit a long‐term memory response.

II. To compare the adenoma recurrence rate from surveillance exams occurring at least 1 year and up to 3 years after week 0 vaccine administration - MUC1 versus placebo.

III. To compare the adenoma recurrence rates between MUC1 and placebo by excluding the following types of adenomas: participants with adenomas =< 5 mm; participants with adenomatous tissue which may represent residual adenoma at the site of the previous advanced adenoma; participants with adenomatous tissue detected in the same segment of the bowel as the previous advanced adenoma.

IV. To assess adverse events to the MUC1 peptide vaccine in comparison to placebo during Parts I and II.

V. To assess patient reported injection site reaction events from the Vaccine Report Card.

TERTIARY OBJECTIVES:

I. To compare the anti‐MUC1 antibody titer at the time of surveillance colonoscopy for the purpose of evaluating the anti‐MUC1 antibody response in relation to adenoma recurrence.

II. To evaluate MUC1 expression on baseline advanced adenomas and on recurrent adenomas detected at surveillance colonoscopy.

III. To evaluate levels of circulating myeloid derived suppressor cells (MDSC) in the vaccinated and the placebo group and correlate with anti‐MUC1 antibody levels and adenoma recurrence.

IV. To establish a biospecimen repository archive including live cells, plasma, and germline deoxyribonucleic acid (DNA) for future immunologic (e.g. MUC1‐specific T cells) and other assays (systems biology approach to detect differences between responders and non‐responders), testing not currently accommodated within the budget of this trial.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine subcutaneously (SC) in weeks 0, 2 and 10 and a booster injection in week 53.

ARM II: Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.

After completion of treatment, patients are followed up every 6 months for up to 3 years. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT02886000
Study type Interventional
Source Mayo Clinic
Contact
Status Recruiting
Phase Phase 2
Start date June 2014

See also
  Status Clinical Trial Phase
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT04516785 - Reducing Colonoscopies in Patients Without Significant Bowel Disease
Recruiting NCT05381792 - Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia
Withdrawn NCT05606081 - Predicting Risk for Post-polypectomy Colorectal Cancer N/A
Recruiting NCT05576506 - Application of Hyperspectral Imaging Analysis Technology in the Diagnosis of Colorectal Cancer Based on Colonoscopic Biopsy
Active, not recruiting NCT03796884 - Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Phase 2
Completed NCT05508503 - A Study on a Blood-based Dual-target Test for CRC Detection
Recruiting NCT02935049 - Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique N/A
Completed NCT05477836 - Feasibility and Safety of MiWEndo-assisted Colonoscopy N/A
Active, not recruiting NCT05740137 - Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy N/A
Active, not recruiting NCT05754229 - Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy N/A
Completed NCT03234725 - Analysis of New Endoscopic Features and Variable Stiffness in Colonoscopy: Prospective Randomised Trial
Completed NCT05913453 - Technical Failure During Colorectal Endoscopic Full Thickness Resection (EFTR): The "Through Thick and Thin" Study
Recruiting NCT05261932 - Research on Endoscopic Precision Biopsy.
Completed NCT02521727 - To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas
Completed NCT02226185 - Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence Phase 2/Phase 3
Completed NCT00298545 - Effect of Vitamin D and Calcium on Genes in the Colon Phase 1
Completed NCT03268655 - Ginger and Gut Microbiome (GINGER) N/A
Active, not recruiting NCT04952129 - Optimal Selenium for Bowel Polyps (OSCAR) Phase 1
Recruiting NCT04444908 - Development and Validation of an Artificial Intelligence-assisted Strategy Selection System for Colonoscopy Cleaning